With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.211108-50-8,tert-Butyl 3-fluoro-4-oxopiperidine-1-carboxylate,as a common compound, the synthetic route is as follows.
Sodium hydride in mineral oil (60percent, 0.18 g, 4.6 mmol) was suspended in THF (12 mL) and methyl 2-(dimethoxyphosphoryl)acetate (0.84 g, 4.6 mmol) was added drop wiseat 0 C. The reaction mixture was stirred at 0 00 for 1 h then tert-butyl-3-fluoro-4-oxo- piperidine-1-carboxylate (1.0 g, 4.6 mmol) in THF (5 mL) was added drop wise at 0 C. The reaction mixture was stirred at rtfor 16 h, then quenched with water (10 mL). The reaction mixture was extracted with EtOAc (3 x 20 mL), the organic layers were combined and washed with sat. NaHCO3 sol. (20 mL) and brine (20 mL) then dried(Na2504). The solvents were removed in vacuo and the residue was purified by column chromatography (normal phase, [Biotage SNAP cartridge KP-sil 25 g, 40-63 tim, 60 A, 25 mL per mm, gradient 0percent to 35percent EtOAc in Isohexane]) to give teit-butyl 3-fluoro-4-(2-methoxy-2-oxoethyl idene)pi peridine- 1 -carboxylate (0.94 g, 75percent).1H NMR: (400 MHz, DMSO-d6) oe: 1.39 (d, J = 2.5 Hz, 9 H), 2.20 – 2.35 (m, 1 H), 2.74 -2.96 (m, 2 H), 3.64 (d, J= 2.0 Hz, 3 H), 4.02-4.20 (m, 1 H), 4.22-4.43 (m, 1H), 5.05(ddd, J= 47.5, 4.5, 3.5 Hz, 1 H), 5.98 (5, 1 H), 6.19 (5, 0.5H), 6.31 (5, 0.5H)
211108-50-8, The synthetic route of 211108-50-8 has been constantly updated, and we look forward to future research findings.
Reference£º
Patent; HEPTARES THERAPEUTICS LIMITED; CONGREVE, Miles Stuart; BROWN, Giles Albert; TEHAN, Benjamin Gerald; PICKWORTH, Mark; CANSFIELD, Julie Elaine; (105 pag.)WO2015/140559; (2015); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem